Ozempic and Trulicity belong to the same group of drugs, called glucagon-like peptide-1 (GLP-1) receptor agonists. Mounjaro belongs to a similar group of drugs, called GLP-1 and glucose-dependent ...

Insights, news and analysis of the crypto market straight to your inbox ...

US-based pharmaceutical giant Eli Lilly has launched its diabetes and weight-loss drug, Mounjaro, in India, following approval from the Central Drugs Standard Control Organisation (CDSCO).

Eli Lilly launches weight-loss drug Mounjaro in India (AI-Generated) Guess what? There's this shot you can get—Rs 14,000 a month—for weight loss. But, but, but… India’s obesity problem is no small fry ...

Pharma giant Eli Lilly has launched Mounjaro, a popular weight-loss drug, in India. Priced at Rs 3,500 for 2.5 mg and Rs 4,375 for 5 mg, Mounjaro is available by prescription and aims to address ...

The new class of weight-loss medicines that has taken the world by a storm will now become available in India, with the pharmaceutical giant Eli Lilly on Thursday announcing the launch of tirzepatide ...

Eli Lilly and Company launched its weight loss drug Mounjaro in India on Thursday after obtaining approval from the Central Drugs Standard Control Organisation (CDSCO). This is a drug which ...

Eli Lilly launched Mounjaro, a weight-loss injectable, in India, priced at ₹4,375 for 5 mg, targeting obesity and type-2 diabetes management. American drugmaker Eli Lilly and Company launched ...

US pharma giant Eli Lilly's obesity management drug Mounjaro has now been launched in India. Interestingly, compared to the US, the price of Mounjaro in India will be one-fifth. Apart from obesity, ...

In a single-dose vial presentation Eli Lilly, a pharmaceutical firm has announced the launch of Mounjaro, following the authorization from the Central Drugs Standard Control Organization (CDSCO). The ...

Mounjaro injectable prescription medication designed to aid weight loss and manage Type 2 diabetes. It belongs to a new class of medications that act as both glucose-dependent insulinotropic ...